Clinical Trial Results: To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and tolerability of a fixed-dose combination of obeticholic acid and bezafibrate in primary biliary cholangitis was terminated; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Obeticholic acid and bezafibrate fixed-dose combination

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: TERMINATED | Results posted: 2026-06-08